BLRX News and Press, BioLineRx Ltd.

2026-05-29 14:36:10 ET Image source: The Motley Fool. May 26, 2021 Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-27 10:47:04 ET BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call May 27, 2026 8:30 AM EDT Company Participants Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer ... Read the full article...

2026-05-27 07:08:02 ET More on BioLineRx BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioLineRx Historical earnings data for BioLineRx Financial information for BioLineRx Read the full article on Seek...

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM...

2026-05-26 10:10:34 ET More on BioLineRx BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioLineRx Historical earnings data for BioLineRx Financial information for BioLineRx Read the full article on Seek...

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO, Norway , May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biophar...

BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-c...

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts PR Newswire New preclinical data further demonstrate GLIX1...

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PR Newswire Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain an...

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PR Newswire GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma  and other cancers   GL...